Boosting Regulatory T Cells (Tregs) in Type 1 Diabetes Patients - Diabetes Research Institute
The DRI’s Dr. Allison Bayer explains adoptive Treg cell therapy and her team’s efforts to help boost these key immune cells and rebalance the immune system. Her current findings have shown that Tregs may prevent transplant rejection and well as reverse autoimmunity.
Dr. Bayer’s research focuses on understanding the basic immunobiology of regulatory T cells and applying that knowledge for future clinical applications. She hopes that her work will lead to the design of novel therapies for a non-toxic approach for the treatment of type 1 diabetes patients.